<DOC>
	<DOC>NCT01661283</DOC>
	<brief_summary>To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of everolimus in combination with bevacizumab in individuals with MPNST</brief_summary>
	<brief_title>SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients 18 or older Unresectable or metastatic sporadic or NF1 associated highgrade MPNST Experienced progression after one or more prior regimens of cytotoxic chemotherapy Patients must be able to swallow tablets Patients must have measurable disease, defined as at least one tumor that is measurable Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a previously radiated field may be enrolled if it has been at least 4 weeks since the last dose of radiation therapy Patients must have recovered from the toxic effects of all prior therapy before entering this study Adequate organ function ECOG performance status of 0, 1, or 2 Patents who received an anthracycline prior to enrollment must have an ejection fraction â‰¥ 50% Subjects of childbearing potential requires acceptable form of birth control Informed consent Patients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug or patients receiving prior treatment with investigational drugs 4 weeks of the start of study drug Patients may not be currently receiving strong inhibitors of CYP3A4, and may not have received these medications within 1 week of entry Prior radiotherapy within 4 weeks of the start of study drug Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, Patients who have not recovered from the side effects of any major surgery Patients that may require major surgery during the course of the study Less than 7 days have passed from core biopsies or other minor surgical procedures excluding placement of a vascular access device Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent(Topical or inhaled corticosteroids are allowed) Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study Female patients who are pregnant or breast feeding Patients who have received prior treatment with an mTOR inhibitor or bevacizumab Patients with known hypersensitivity to rapamycins concurrent use of anticoagulant drugs Patients using Seville orange, star fruit, grapefruit and their juices, and St. John's Wort Patients taking enzyme inducing anticonvulsants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MPNST</keyword>
	<keyword>malignant peripheral nerve sheath tumors</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Avastin</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>